Shine Investment Advisory Services’s Neurocrine Biosciences NBIX Stock Holding History

Shine Investment Advisory Services’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$24K	Hold	247	–	–	0.01%	425
2020 Q2	$30K	Buy	247 +107	+76%	+$11.8K	0.01%	397
2020 Q1	$12K	Buy	140 +27	+24%	+$2.64K	0.01%	497
2019 Q4	$12K	Hold	113	–	–	﹤0.01%	545
2019 Q3	$10K	Buy	113 +64	+131%	+$5.98K	﹤0.01%	556
2019 Q2	$4K	Hold	49	–	–	﹤0.01%	636
2019 Q1	$4K	Hold	49	–	–	﹤0.01%	645
2018 Q4	$3K	Sell	49 -49	-50%	-$4.69K	﹤0.01%	641
2018 Q3	$12K	Hold	98	–	–	0.01%	500
2018 Q2	$10K	Sell	98 -64	-40%	-$5.73K	0.01%	525
2018 Q1	$13K	Hold	162	–	–	0.01%	494
2017 Q4	$13K	Hold	162	–	–	0.01%	501
2017 Q3	$10K	Hold	162	–	–	0.01%	528
2017 Q2	$7K	Buy	+162	New	+$7.86K	﹤0.01%	574

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Shine Investment Advisory Services's NBIX Position: Q3 2020 in Review

Shine Investment Advisory Services held its Neurocrine Biosciences (NBIX) position steady in Q3 2020 at 247 shares worth $24K. The position accounts for 0.01% of the portfolio, ranked #425.

Shine Investment Advisory Services first reported a position in NBIX in Q2 2017 and has held it in 14 quarters since. The position peaked at $30K in Q2 2020. 419 funds tracked by Wall St. Rank hold NBIX as of Q3 2020.

Shine Investment Advisory Services held 247 shares of Neurocrine Biosciences worth $24K as of Q3 2020.
Shine Investment Advisory Services left its Neurocrine Biosciences share count unchanged in Q3 2020.
Neurocrine Biosciences made up 0.01% of Shine Investment Advisory Services's portfolio in Q3 2020, its #425 holding.
Shine Investment Advisory Services first reported a position in Neurocrine Biosciences in Q2 2017 and has held it in 14 quarters since.
Shine Investment Advisory Services's Neurocrine Biosciences position peaked at $30K in Q2 2020.
419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2020.

Based on Shine Investment Advisory Services's 13F filing for Q3 2020, filed 3 Nov 2020.